69 results about "Hepatitis B virus core Antigen" patented technology

A needle device for the delivery of therapeutic material into tissue comprising a connection to a pressure generation element, a lumen adapted for the passage of a therapeutic material, and a needle barrel, wherein each needle barrel comprises an opening adapted to control and deliver a pressure transmitted from the pressure generation element into a tissue to cause an increase in the permeability of a cell membrane to the therapeutic material.

The invention discloses the medical application of a 15-methylene replaced andrographolide derivant as shown in general formula 1, more particularly relates to the application thereof in preparing anti-hepatitis B virus drugs, pertaining to the pharmaceutical chemistry field. HepG2.2.15 cells are used for detecting the secretory volumes of HBsAg and HBeAg and the HBV DNA level related to viral particles in the supernatant liquid of a nutrient solution, and the result shows that the 15-methylene replaced andrographolide derivant has good in-vitro anti-HBV effect. The 15-methylene replaced andrographolide derivant has better development and application prospect by being applied in preparing drugs used for treating and preventing Hepatitis B.

The present invention discloses an enzyme association immunity test reagent kit and its operation instruction to test hepatitis B core antigen. Wherein, the reagent kit mainly comprises a monoclonal hepatitis B core antigen prepackaged micro-perforated plate, sample processing agent and polyclone hepatitis B core antigens marked with horse radish peroxidase. During operation, a sample to be tested is firstly preprocessed with the sample processing agent and then added into the monoclonal hepatitis B core antigen prepackaged micro-perforated plate. And then, polyclone hepatitis B core antigens marked with horse radish peroxidase and zymolytes are added to colorize. Stop solution is added to stop reaction and finally the measuring result is confirmed through color comparison. The present invention can detect hepatitis B core antigen in blood serum, ensure quite high conformance ratio in aspect of HBV-DNA detecting result, achieve requirements of clinical examination, have characteristics of convenience, sensitivity and stability, supplement conventional hepatitis B virus detecting method and bring better clinical operation.

The invention relates to the field of molecular biology and immunology, in particular to an application of an HBcAg (hepatitis B core antigen) virus-like particle serving as a cervical cancer therapeutic vaccine carrier. A preparation method comprises steps as follows: an HPV16 E749-57CTLs epitope peptide fragment is selected, a DNA (deoxyribose nucleic acid ) fragment of the HPV16 E749-57CTLs epitope peptide fragment is inserted between 78 and 79 amino acids of the HBcAg through genetic recombination, an obtained recombinant plasmid pHBcAg-E749-57 is converted into Escherichia coli DH5alpha, and an HBcAg virus-like particle vaccine presenting E749-57 is obtained after induction expression and purification. After a tumor-bearing mouse is immunized with the virus-like particle vaccine, the body of the mouse can be induced to generate a higher HPV16E7 specific cellular immunologic response, and growth of tumors is remarkably inhibited.

A therapeutic DC vaccine for preventing and treating chronic hepatitis B is a hepatitis B specific DC vaccine carried by both HBsAg and HBcAg. The dendritic cells coming from mononuclear cells are carried by both recombinant HBV surface antigen and recombinant HBV core antigen.

The invention discloses a compound of a hepatitis B virus antigen and lewis oligosaccharide and a preparation method and application thereof. The compound is prepared mainly through combination of a core hepatitis B virus antigen and lewis oligosaccharides-x. The preparation method comprises the following steps: preparing a conjugate of the core hepatitis B virus antigen and streptavidin, and combining the conjugate with (lewis oligosaccharides-x)-sodium polyacrylate-biotin through high affinity of the streptavidin and the biotin, thereby preparing the compound of the hepatitis B virus antigen and the lewis oligosaccharide. The compound enhances the capability of recognition of a immune system to the hepatitis B virus due to the active targeting of dendritic cells through the high affinity of the lewis oligosaccharides-x and DC-SIGN, can activate specific CTL responses and induce strong anti-viral immunity, and can be applied in the preparation of vaccines for treatment of the hepatitis B.

The invention discloses a hepatitis B virus dendritic cell therapeutic vaccine and a preparation method thereof. The preparation method thereof includes the steps that: HBcAg-Fc digenic co-expression recombinant eukaryotic vector is constructed; the obtained digenic co-expression recombinant eukaryotic vector is added with saponin Quil A and then is added with cholesterol and lecithin, ice-bath ultrasonic processing is carried out, so that solution is fully mixed and emulsified, PBS dialysis is carried out, and the obtained micro floccus is immunostimulating complex; and the obtained immunostimulating complex activates and simulates dendritic cell, thus obtaining the cell therapeutic vaccine. The vaccine carries out high efficiency transfection on dendritic cell, the generated fusion protein targets the dendritic cell in high efficiency by virtue of Fc segment, thus activating the dendritic cell, promoting immune response of hepatitis B virus core antigen specificity T cell and inducing the antivirus replication capability of immune cell in high efficiency, so that the vaccine can be taken as hepatitis B virus therapeutic vaccine.

The invention relates to a recombination broad-spectrum vaccine specific to Human enterovirus 71. The invention constructs a fusion protein which comprises at least one copied peptide SP55 and/or SP70 of Human enterovirus 71 VP1 protein and a hepatitis B virus core antigen. The fusion protein can renature and assemble by self in a solubility manner after being expressed, denatured and purified, thereby forming virus-like particles with strong immunogenicity; and the virus-like particles can induce the generation of a broad-spectrum neutralizing antibody with high valence in vivo, thereby being capable of serving as the vaccine for preventing diseases related to Human enterovirus 71 infection. According to the invention, suitable carriers for forming the virus-like particles are found for antigens deriving from the enterovirus 71 VP1 protein, thereby the formed virus-like particles properly expose the antigens and increase the immunogenicity of the antigens.

The invention relates to a recombinant fusion protein HSP65-HbcAg, which is fused from heat shock protein 65 and multi-epitope hepatitis B virus HbcAg, in the recombinant fusion protein, the multi-epitope hepatitis B virus HbcAg comprises 5 different antigen epitopes through interconnection by mathematical combination modes. the recombinant fusion protein can make hepatitis B virus HbcAg specific cell toxic T lymphocyte CTL eradicate the cells infected by hepatitis B virus, thus achieving the goal of treating and/or preventing hepatitis B. The invention also provides the nucleic acid sequence encoding the recombination fusion protein.

The present invention provides an agent for the treatment or prophylaxis of arteriosclerosis comprising an expression vector encoding a chimeric Hepatitis B virus core antigen polypeptide inserted with an amino acid sequence containing a specific epitope of apolipoprotein (a), wherein the amino acid sequence containing the specific epitope is inserted between the amino acid residues 80 and 81 of the hepatitis B virus core antigen polypeptide.

The present invention provides a therapeutic or improving agent for a lifestyle-related disease, containing an expression vector encoding a chimeric Hepatitis B virus core antigen polypeptide inserted with an amino acid sequence containing a specific epitope of the lifestyle-related disease-related factor, wherein the amino acid sequence containing the specific epitope is inserted between the amino acid residues 80 and 81 of the hepatitis B virus core antigen polypeptide.

The invention relates to an antigen epitope, in particular to an immune dominant HLA-A3 (human leukocyte antigen A3) super-type restrictive CTL (cytotoxic T lymphocyte) epitope of a hepatitis B virus core antigen (HBcAg) and an identification method for the super-type CTL epitope. The super-type CTL epitope consists of the following amino acid sequence: Leu-Leu-Asp-Thr-Ala-Ser-Ala-Leu-Tyr-Arg. The method is also suitable for identification of other antigen super-type CTL epitopes, and can provide a useful tool for design and research of therapeutic polypeptide vaccines. The invention also relates to application of the super-type CTL epitope in preparing hepatitis B therapeutic polypeptide vaccines, and provides a new strategy and a new method for efficient research of the hepatitis B therapeutic polypeptide vaccines. The method is expected to break through hepatitis B immune tolerance, reconstruct the immune function of cells and efficiently inhibit and clear hepatitis B viruses.

The invention discloses a CTGF (connective tissue growth factor) chimeric vaccine for treating liver fibrosis. The antigenic epitope of the CTGF is inserted into c/e1B cell epitope of hepatitis b virus core antigen to form the CTGF chimeric vaccine which can be assembled into hepatitis B core sample particles. Under the non-adjuvant assistance, the chimeric vaccine can stimulate a body to generate high-valence anti-CTGF neutral antibody. A mouse which is immunized by the chimeric vaccine is obviously relieved in fibrosis degree generated after carbon tetrachloride induction. According to the experimental verification, the CTGF chimeric vaccine can be used for obviously restraining the activation intensity of hepatic stellate cells in the mouse liver, and also can be used for stimulating liver cells to multiply and restraining liver apoptosis. Besides, the TGF-beta 1 and PDGF level in the immunized mouse is obviously reduced, so that the process of liver fibrosis can be relieved in a facilitated manner. According to the results, the CTGF chimeric vaccine can be used for successfully restraining the carbon-tetrachloride-induced mouse liver fibrosis. Therefore, the CTGF chimeric vaccine is expected to be developed into effective means for treating the liver fibrosis.

The invention provides a recombinant virus-like granule and a preparation method and application thereof. The method comprises the following steps that cells expressing the recombinant virus capsid protein are fermented, then fermentation products are collected, a 2-6-M urea solution is adopted for dissolving and depolymerization, and an intact virus-like granule of the recombinant viral capsid protein is obtained through extracellular secondary assembly. According to the preparation method of the recombinant hepatitis B virus core antigen granule, the recombinant capsid protein precipitated by ammonium sulphate is dissolved, depolymerized and purified under relatively mild conditions, and finally extracellular secondary assembling is conducted to form the virus-like granule with a naturalstructure. The method is simple and efficient, and the prepared recombinant hepatitis B virus core antigen granule has the advantages of being complete and uniform in structure and free of host nucleic acid and miscellaneous protein. The granule has the important significance and broad application prospects.

The invention provides an immunity-enhanced type virus-like particle for presenting recombinant cat sensitinogen rFel d 1 protein, an expression vector of the immunity-enhanced type virus-like particle and preparation and application of the immunity-enhanced type virus-like particle. The protein subunit forming the virus-like particle is fused protein of hepatitis B core antigen and polypeptides with the amino acid sequence of SEQ ID NO:1. The amino acid sequence of the fused protein is formed by inserting the sequence SEQ ID NO:1 of polypeptides between the 78th to 81st amino acid of hepatitis B core antigen and replacing the 79th to 80th amino acid of hepatitis B core antigen. By means of HBcAg-fFel d 1 fused protein, the immunogenicity of fFel d 1 can be remarkably improved, and therefore the detection sensitivity of fFel d 1 recombined and expressed in vitro in application of in-vitro diagnosis cat allergies is improved.

The fusion virus-like particle contains protein capable of forming virus-like particle as carrier and fused protective target virus antigen. Specifically, human hepatitis B virus core antigen forming virus-like particle is used as the carrier, and protective target virus antigen gene segment is fused in to form fused virus-like particle, which is further mixed with adjuvant, if any, to form vaccine. The target antigen may display its surface to produce relatively high B cell activity and stimulate T cell to produce protective immunity. During use, the vaccine may be made to enter body via injection, spraying, oral taking, dropping to nose or eye, penetration, absorption or physical and chemical mediation.

The invention belongs to the field of molecular immunity and relates to an aptamer sequence for a hepatitis B virus (HBV) core antigen and an application of the nucleic aptamer sequence. According to the invention, a gene-recombination plasmid is adopted to express the core antigen, and an aptamer specially bound with the core antigen is screened, so as to prepare a characteristic sequence CATTT with the special binding HBV core antigen. The characteristic sequence is the base of the special binding of the aptamer and the HBc (hepatitis B core) antigen, can be used for drug design and the preparation of drugs and other products; and the aptamer with the characteristic sequence can be used as a probe or therapeutic target resisting to HBV to design and prepare drugs or agents resisting to HBV.

The invention discloses an HLA-DR9 restrictive regulatory T cell epitope of Hepatitis B virus core antigen and e antigen, which is composed of the following amino acid sequence: SRDLVVNYVNTNMGLKIRQLLWFHI. The invention also discloses an application of a regulatory T cell epitope in preparing hepatitis B therapeutic vaccine containing the Hepatitis B virus core antigen and e antigen, namely when the hepatitis B therapeutic vaccine containing the Hepatitis B virus core antigen and/or e antigen is prepared, the regulatory T cell epitope with immunosuppressive action in the Hepatitis B virus coreantigen and/or e antigen is eliminated. The invention provides a new strategy and a method for development of the high-efficient hepatitis B therapeutic vaccine, is expected to break hepatitis B immune tolerance, rebuilds cellular immune function and effectively inhibits and eliminates the hepatitis B virus.